WTA
PCVX icon

Washington Trust Advisors’s Vaxcyte PCVX Stock Holding History

Washington Trust Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-61
Closed -$1.98K – 709
2025
Q2 		$1.98K Hold
61
– – ﹤0.01% 612
2025
Q1 		$2.3K Hold
61
– – ﹤0.01% 606
2024
Q4 		$4.99K Hold
61
– – ﹤0.01% 568
2024
Q3 		$6.97K Hold
61
– – ﹤0.01% 529
2024
Q2 		$4.61K Hold
61
– – ﹤0.01% 573
2024
Q1 		$4.17K Hold
61
– – ﹤0.01% 594
2023
Q4 		$3.83K Buy
61
+29
+91% +$1.51K ﹤0.01% 600
2023
Q3 		$1.63K Hold
32
– – ﹤0.01% 652
2023
Q2 		$1.6K Hold
32
– – ﹤0.01% 634
2023
Q1 		$1.2K Buy
+32
New +$1.36K ﹤0.01% 755

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Washington Trust Advisors's PCVX Position: Q3 2025 in Review

Washington Trust Advisors sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 61 shares — an estimated $1.98K sold.

Washington Trust Advisors first reported a position in PCVX in Q1 2023 and held it in 10 quarters. The position peaked at $6.97K in Q3 2024. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

  • Washington Trust Advisors reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
  • Washington Trust Advisors sold 61 Vaxcyte shares in Q3 2025, an estimated $1.98K.
  • Washington Trust Advisors first reported a position in Vaxcyte in Q1 2023 and held it in 10 quarters.
  • Washington Trust Advisors's Vaxcyte position peaked at $6.97K in Q3 2024.
  • 285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Washington Trust Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.